Study challenges the use of biochemical recurrence as prostate cancer predictor

A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival.

Related Keywords

Amar Kishan ,Soumyajit Roy ,Danielle Ellis ,Tahmineh Romero ,Health Jonsson Comprehensive Cancer Center ,David Geffen School Of Medicine ,Rush University Medical Center ,David Geffen School ,Jonsson Comprehensive Cancer Center ,Rush University Medical ,Cancer ,Prostate ,Prostate Cancer ,Androgen ,Androgen Deprivation Therapy ,Ntigen ,Ncology ,Prostate Specific Antigen ,Radiation Therapy ,Radiotherapy ,